Shire gets FDA’s blessing for Motegrity
The Food and Drug Administration has green lighted Shire’s Motegrity (prucalopride), a once-daily, oral treatment option for adults with Chronic Idiopathic Constipation, or CIC.
Motegrity, a selective serotonin-4 (5-HT4) receptor agonist, provides a different class of treatment for CIC that works by enhancing colonic peristalsis to increase bowel motility.
Motegrity is expected to launch in 2019 in the United States where an estimated 35 million adults are living with CIC.
“The approval of Motegrity marks a new day in the treatment of CIC,” Shire senior vice president and chief medical officer Howard Mayer said. “This significant milestone reinforces our continued commitment to the GI community and advances our goal of addressing the unmet need of patients suffering from rare, specialized and common GI conditions.”
Motegrity, a selective serotonin-4 (5-HT4) receptor agonist, provides a different class of treatment for CIC that works by enhancing colonic peristalsis to increase bowel motility.
Motegrity is expected to launch in 2019 in the United States where an estimated 35 million adults are living with CIC.
“The approval of Motegrity marks a new day in the treatment of CIC,” Shire senior vice president and chief medical officer Howard Mayer said. “This significant milestone reinforces our continued commitment to the GI community and advances our goal of addressing the unmet need of patients suffering from rare, specialized and common GI conditions.”